Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

News & Events

ATAR exams – special provisions

End-of-year exams may be far from the minds of students managing diabetes but now is the time to get the process started for obtaining special ATAR provisions.

News & Events

Meet Lucy

Learn about Lucy's journey through the eyes of her mum, and through the video "T1D: Our Lucy".

News & Events

Driving and Diabetes

Getting a driver's license is an important milestone for a young adult in terms of gaining independence, including young people with diabetes.

Videos

Check out the Centre's video library here

Research

Causal Impact of Physical Activity on Child Health and Development

The relationship between physical activity and child health and development is well-documented, yet the extant literature provides limited causal insight into the amount of physical activity considered optimal for improving any given health or developmental outcome.

Research

The course and prognostic capability of motor difficulties in infants showing early signs of autism

Delays within the motor domain are often overlooked as an early surveillance marker for autism. The present study evaluated motor difficulties and its potential as an early predictive marker for later autism likelihood in a cohort of infants showing early behavioral signs of autism aged 9-14 months. The motor domain was evaluated using the motor subscales of the Mullen Scales of Early Learning at baseline, and at a 6-month follow-up.

Research

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia

Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim of this study was to determine the preclinical efficacy of the selective proteasome inhibitor carfilzomib, for infants with KMT2A-rearranged ALL.